Tracking Therapeutic Progress of Gene-Editing Agent PBGENE-DMD for Duchenne Muscular Dystrophy
Two-Year CHIMES Study Data Highlight Effect of Ocrelizumab in Diverse Relapsing MS Patient Population
Next Frontier of Research in Multiple Sclerosis Remyelination
NeuroVoices: Elisabeth Sonesson, PhD, on Imlifidase’s Targeted, Fast-Acting Approach to GBS